MYELOMA **DIAGNOSIS PATHWAY**

Myeloma, also known as multiple myeloma, is a rare bone marrow cancer arising from the plasma cells. In Europe, there are around **50,000 new cases diagnosed each year**.



SUSPECT MYELOMA?

Myeloma signs and symptoms

If a patient presents with one or more of the following unexplained symptoms, consider testing for myeloma.

- Bone pain / back pain, usually presents as unexplained pain, generalised or localised
- Urine changes, such as foaming urine or passing excessive or very little urine
- Unintentional weight loss
- Breathlessness
- Spontaneous fractures, including osteoporotic vertebral fractures



Recurrent infections

Fatigue and



There are four defining features of myeloma, known as **CRAB** crit<u>eria:</u>

Elevated **C**alcium

Renal impairment /failure

Anaemia

Bone disease



REFERRAL AND **FURTHER INVESTIGATIONS**

If initial tests and investigations suggest myeloma, or a patient has unresolved presenting symptoms, they should be referred to a haematology clinic and further investigations are required to confirm diagnosis:

- Bone marrow aspirate / biopsy
- X-Ray, skeletal survey
- Low dose whole-body CT
- Whole body MRI
- PET/CT



Adapted from the Myeloma UK Myeloma Diagnosis Pathway, with permission.

THINK MYELOMA!

Myeloma tests and investigations

If you suspect a patient has myeloma, you should conduct the following tests and investigations:

Full blood count and blood chemistry

- Full blood count: look for unexplained anaemia
 - Erythrocyte sedimentation rate (ESR): usually elevated
- Urea and electrolytes (U&Es): to check for renal impairment
- Serum creatinine



- Urine and serum protein electrophoresis: to check the presence of paraprotein
- Serum free light chain assay (sFLC), if unavailable, urine
- Urine tests (spot urine tests, 24-hour urine collection and Bence Jones protein test)
- Serum immunoglobulins (IgG, IgA and IgM)

Additional tests to consider

- Serum albumin
- Beta-2 microglobulin
- C-reactive protein
- Calcium: to test for hypercalcaemia
- Lactate dehydrogenase test (LDH)
- Estimated Glomerular Filtration Rate (eGFR)





RELATED DIAGNOSIS

Monoclonal gammopathy of undetermined significance (MGUS)

No treatment - monitor

Progression to AL amyloidosis, myeloma or solitary plasmacytoma: 1% per year

Smouldering mveloma

No treatment - monitor

Progression to myeloma: 10% per year

ADDITIONAL RESOURCES

- 1. European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. Haematologica, 2018; 103 (11); 1772-1784.
- 2. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis. treatment and follow-up. Annals of Oncology. 2021: 32 (3): 309-322.





